| |
|
|
| |
| |
Notes |
|
2009
R’million |
|
|
Restated
2008
R’million |
|
| CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
|
|
|
| Cash generated from operations |
A |
|
2 160,6 |
|
|
1 058,1 |
|
| Financing costs paid |
B |
|
(759,3) |
|
|
(347,5) |
|
| Investment income received |
C |
|
224,2 |
|
|
263,4 |
|
| Tax paid |
D |
|
(333,4) |
|
|
(321,6) |
|
| Net cash generated from operating activities |
|
|
1 292,1 |
|
|
652,4 |
|
| CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
|
|
|
|
| Replacement capital expenditure – property, plant and equipment |
|
|
(97,0) |
|
|
(79,3) |
|
| Expansion capital expenditure – property, plant and equipment |
|
|
(529,7) |
|
|
(300,0) |
|
| Proceeds on disposal of property, plant and equipment |
|
|
9,1 |
|
|
3,2 |
|
| Expansion capital expenditure – intangible assets |
|
|
(626,8) |
|
|
(162,3) |
|
| Expansion capital expenditure – GSK brands |
|
|
(2 653,0) |
|
|
– |
|
| Replacement capital expenditure – intangible assets |
|
|
(0,1) |
|
|
(3,7) |
|
| Proceeds on disposal of intangible assets |
|
|
15,5 |
|
|
55,2 |
|
| Acquisition of subsidiaries and joint ventures |
E |
|
102,9 |
|
|
(1 357,5) |
|
| Disposal of joint venture and subsidiary |
F |
|
326,3 |
|
|
10,1 |
|
| (Increase)/decrease in other non-current financial receivables |
|
|
(0,4) |
|
|
1,2 |
|
| Redemption of investment in preference shares |
|
|
— |
|
|
376,8 |
|
| Payment of outstanding Oncology business purchase consideration |
G |
|
(103,5) |
|
|
— |
|
| Net cash used in investing activities |
|
|
(3 556,7) |
|
|
(1 456,3) |
|
| CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
|
|
|
|
| Proceeds from borrowings |
|
|
6 256,2 |
|
|
5 004,3 |
|
| Repayment of borrowings |
|
|
(3 134,6) |
|
|
(3 506,5) |
|
| Proceeds from deferred-payables |
|
|
— |
|
|
9,5 |
|
| Repayment of deferred-payables |
|
|
(12,2) |
|
|
(64,5) |
|
| Dividends paid |
|
|
(0,8) |
|
|
(1,5) |
|
| Proceeds from issue of ordinary shares |
|
|
20,4 |
|
|
15,3 |
|
| Capital distribution paid |
|
|
— |
|
|
(245,9) |
|
| Net cash generated from financing activities |
|
|
3 129,0 |
|
|
1 210,7 |
|
| Movement in cash and cash equivalents before exchange rate changes |
|
|
864,4 |
|
|
406,8 |
|
| Effects of exchange rate changes |
|
|
(486,4) |
|
|
40,6 |
|
| CASH AND CASH EQUIVALENTS |
|
|
|
|
|
|
|
| Movement in cash and cash equivalents |
|
|
378,0 |
|
|
447,4 |
|
Cash and cash equivalents at the beginning
of the year |
|
|
944,9 |
|
|
497,5 |
|
| Cash and cash equivalents at the end of the year |
H |
|
1 322,9 |
|
|
944,9 |
|
| Discontinued operations are included in both the 2009 and 2008 statement of cash flows. |
|
|
|
|
| |
|
|
|
